Pfizer

Pfizer faced a massive increase in R&D burden after absorbing multiple companies via M&A (Metsera, 3SBio, Seagen) while needing to control costs. Administrative overhead was high, including the need to individually adapt promotional materials for each jurisdiction's regulatory requirements.

Pfizer deployed AI across every function—R&D, legal, manufacturing, marketing, and commercial. AI engineers were paired with scientists to measure productivity. Field forces were trained using AI, marketing strategies were tailored algorithmically, and promotional material adaptation across markets was automated. The company also invested in 1,200+ additional GPUs to expand AI infrastructure.

Pfizer slashed billions in spending across R&D and administrative operations. Selling, informational, and administrative expenses declined. The company improved productivity rather than just cutting headcount, enabling it to absorb more R&D substrate while planning $11 billion in R&D spending for 2026.

• AI-driven productivity gains can offset the R&D burden of major M&A activity without proportional headcount growth.
• Commercial AI use cases (field force training, marketing personalization, regulatory material adaptation) can deliver near-term ROI alongside R&D applications.
• Embedding AI engineers directly with scientists creates measurable productivity accountability.